Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease

Cavagna, Lorenzo; Caporali, Roberto; Abdi-Ali, Lul; Dore, Roberto; Meloni, Federica; Montecucco, Carlomaurizio

doi:10.3899/jrheum.121026

Cited by 90 publications

(70 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cyclosporin A can be prescribed as a single drug, or in combination with other immunosuppressive drugs in severe cases [58,93,97]. It seems to be effective as both a first-or second-line therapy in rapidly progressive ILD [103,106]. In chronic ILD, an efficacy of 55% has been reported when used as a first-line treatment (table 5) [86,92,97,100]; all patients responded to treatment when cyclosporin A was used as second-line in three small series [93,102,103].…”

Section: Methotrexatementioning

confidence: 99%

“…It seems to be effective as both a first-or second-line therapy in rapidly progressive ILD [103,106]. In chronic ILD, an efficacy of 55% has been reported when used as a first-line treatment (table 5) [86,92,97,100]; all patients responded to treatment when cyclosporin A was used as second-line in three small series [93,102,103]. In rapidly progressive ILD, cyclosporin A may be used as a first-line or second-line agent with response ranges of 56-80%, and 23-80%, respectively (table 5) [62,58,93,96,97,100].…”

Section: Methotrexatementioning

confidence: 99%

See 1 more Smart Citation

Idiopathic inflammatory myopathies and the lung

et al. 2015

View full text Add to dashboard Cite

Idiopathic inflammatory myositis (IIM) is a group of rare connective tissue diseases (CTDs) characterised by muscular and extramuscular signs, in which lung involvement is a challenging issue. Interstitial lung disease (ILD) is the hallmark of pulmonary involvement in IIM, and causes morbidity and mortality, resulting in an estimated excess mortality of 50% in some series. Except for inclusion body myositis, these extrapulmonary disorders are associated with the general and visceral involvement frequently found in other CTDs including fever, Raynaud's phenomenon, arthralgia, nonspecific cutaneous modifications and ILD, for which the prevalence is estimated to be up to 65%. Substantial heterogeneity exists within the spectrum of IIMs, and each condition is associated with various frequencies and subtypes of pulmonary involvement. This heterogeneity is partly related to the presence of various autoantibodies encompassing anti-synthetase, anti-MDA5 and anti-PM/Scl. ILD is present in all subsets of IIM including juvenile myositis, but is more frequent in dermatomyositis and overlap myositis. IIM can also be associated with other presentations of respiratory involvement, namely pulmonary arterial hypertension, pleural disease, infections, drug-induced toxicity, malignancy and respiratory muscle weakness. Here, we critically review the current knowledge about adult and juvenile myositis-associated lung disease with a detailed description of therapeutics for chronic and rapidly progressive ILD. @ERSpublications Interstitial lung disease is a leading cause of morbidity in dermatomyositis/polymyositis

show abstract

Section: Methotrexatementioning

confidence: 99%

Section: Methotrexatementioning

confidence: 99%

Idiopathic inflammatory myopathies and the lung

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In 1998, the first nation-wide survey for the treatment with CSA in IP associated with CTDs was conducted in Japan, and the efficacy of a combination therapy with CSA and corticosteroids in PM/DM associated IP was indicated [176]. A number of retrospective and open-label studies have supported the benefit of CSA for the treatment of ILD with PM/DM [177][178][179][180][181].…”

Section: Management Of Interstitial Pneumonia Associated With Connectmentioning

confidence: 99%

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Ishii¹

2017

Contemporary Topics of Pneumonia

View full text Add to dashboard Cite

Interstitial pneumonia (IP) refers to involvement of the lung parenchyma by varying degrees of inflammation and fibrosis, in contrast to airspace disease typically seen in bacterial pneumonia. IP lies in the center of a heterogenous group of diffuse interstitial lung diseases (ILDs), either idiopathic or linked to underlying disorders. One of the major categories of disorders frequently associated with IP is a connective tissue disease (CTD), in which autoimmunemediated tissue injury leads to multiple organ impairment. Today, IP represents the most critical pulmonary complication in CTD, resulting in significant morbidity and mortality.Despite growing understanding of the pathology of IPs, as well as the accumulating knowledge from both basic and clinical studies of CTDs, the pathogenesis of CTD-associated IP remains unclear. This chapter will provide an overview of the general understanding of ILD and illustrate the current state of knowledge on IP associated with CTD, in order to fully comprehend the entirety of its complex pictures. Moreover, we will propose a new insight into the immune pathogenesis of CTD-IP by presenting evidence which robustly indicates that T cells trigger initial development of IP in polymyositis/dermatomyositis, suggesting potential approaches for controlling such particular T cells in therapeutic interventions for IP.

show abstract

“…Существует несколько гистопатологических вариантов ИПЛ [17], дифференциальная диагностика которых может вызывать затруднения [32]. В таблице представлены различ-ные гистологические модели ИПЛ при РА.…”

unclassified

“…Преобладание модели ОИП отличает ИПЛ при РА от большинства других системных заболеваний соединитель-ной ткани, как правило, характеризующихся преобладани-ем картины НИП [32,34].…”

unclassified

Interstitial lung involvement in rheumatoid arthritis

Бестаев¹,

Bestaeva²

2014

RJTAO

View full text Add to dashboard Cite

Ревматоидный артрит (РА) -системное аутоиммунное ревматическое заболевание неизвестной этиологии, для ко-торого характерны хронический эрозивный артрит и внесу-ставные проявления [1][2][3][4][5][6][7][8]. Поражение легких -одно из ча-стых внесуставных проявлений РА, которое может про-являться патологией бронхиального дерева, ревматоидны-

show abstract

Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease

Abstract: CYC is effective and substantially safe in patients with anti-Jo1 antisynthetase syndrome with corticosteroid-refractory ILD. CYC withdrawal may be associated with ILD relapse, and low-dose CYC was effective in ILD control.

Cited by 90 publications

References 56 publications

Idiopathic inflammatory myopathies and the lung

Idiopathic inflammatory myopathies and the lung

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Interstitial lung involvement in rheumatoid arthritis

Contact Info

Product

Resources

About